Tolero Pharmaceuticals Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
- Financing Rounds
-
5
Tolero Pharmaceuticals General Information
Description
Developer of therapeutics for the treatment of cancer and other diseases created to improving lives of people with serious diseases. The company's therapeutics treatment focuses in the areas of oncology and hematological disorders by developing new therapeutics on a dramatically shortened time-frame and at a much lower cost than traditional drug development, helping patients reduce suffering.
Contact Information
Website
www.toleropharma.comCorporate Office
- 2975 Executive Parkway
- Suite 320
- Lehi, UT 84043
- United States
Corporate Office
- 2975 Executive Parkway
- Suite 320
- Lehi, UT 84043
- United States
Tolero Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tolero Pharmaceuticals Comparisons
Industry
Financing
Details
Tolero Pharmaceuticals Competitors (50)
One of Tolero Pharmaceuticals’s 50 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| FoRx Therapeutics | Venture Capital-Backed | Basel, Switzerland | ||||
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Tolero Pharmaceuticals Patents
Tolero Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11793802-B2 | Treatment of acute myeloid leukemia (aml) with venetoclax failure | Active | 20-Mar-2019 | ||
| US-20220125776-A1 | Treatment of acute myeloid leukemia (aml) with venetoclax failure | Active | 20-Mar-2019 | ||
| WO-2020167990-A1 | Formulations comprising heterocyclic protein kinase inhibitors | Inactive | 12-Feb-2019 | ||
| WO-2020146819-A1 | Alk5 inhibitors for treating myelodysplastic syndrome | Inactive | 10-Jan-2019 | ||
| WO-2020118252-A1 | Methods for treating castration-resistant and castration- sensitive prostate cancer | Inactive | 07-Dec-2018 | A61K31/675 |
Tolero Pharmaceuticals Signals
Tolero Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tolero Pharmaceuticals FAQs
-
When was Tolero Pharmaceuticals founded?
Tolero Pharmaceuticals was founded in 2011.
-
Where is Tolero Pharmaceuticals headquartered?
Tolero Pharmaceuticals is headquartered in Lehi, UT.
-
What is the size of Tolero Pharmaceuticals?
Tolero Pharmaceuticals has 20 total employees.
-
What industry is Tolero Pharmaceuticals in?
Tolero Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Tolero Pharmaceuticals a private or public company?
Tolero Pharmaceuticals is a Private company.
-
What is the current valuation of Tolero Pharmaceuticals?
The current valuation of Tolero Pharmaceuticals is .
-
What is Tolero Pharmaceuticals’s current revenue?
The current revenue for Tolero Pharmaceuticals is .
-
How much funding has Tolero Pharmaceuticals raised over time?
Tolero Pharmaceuticals has raised $22.4M.
-
Who are Tolero Pharmaceuticals’s investors?
Alger, Astex Pharmaceuticals, Black Cliffs Partners, and Orelot have invested in Tolero Pharmaceuticals.
-
Who are Tolero Pharmaceuticals’s competitors?
Voyager Therapeutics, Baliopharm, Centrose, FoRx Therapeutics, and Agios Pharmaceuticals are some of the 50 competitors of Tolero Pharmaceuticals.
-
When was Tolero Pharmaceuticals acquired?
Tolero Pharmaceuticals was acquired on 31-Mar-2017.
-
Who acquired Tolero Pharmaceuticals?
Tolero Pharmaceuticals was acquired by Sumitomo Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process